BACKGROUND: Human gene variants affecting ion channel biophysical activity and/or membrane localization are linked to potentially fatal cardiac arrhythmias. However, the mechanism for many human arrhythmia variants remains undefined despite more than a decade of investigation. Posttranslational modulation of membrane proteins is essential for normal cardiac function. Importantly, aberrant myocyte signaling has been linked to defects in cardiac ion channel posttranslational modifications and disease. We recently identified a novel pathway for posttranslational regulation of the primary cardiac voltage-gated Na(+) channel (Na(v)1.5) by Ca(2+)/calmodulin-dependent protein kinase II (CaMKII). However, a role for this pathway in cardiac disease has not been evaluated. METHODS AND RESULTS: We evaluated the role of CaMKII-dependent phosphorylation in human genetic and acquired disease. We report an unexpected link between a short motif in the Na(v)1.5 DI-DII loop, recently shown to be critical for CaMKII-dependent phosphorylation, and Na(v)1.5 function in monogenic arrhythmia and common heart disease. Experiments in heterologous cells and primary ventricular cardiomyocytes demonstrate that the human arrhythmia susceptibility variants (A572D and Q573E) alter CaMKII-dependent regulation of Na(v)1.5, resulting in abnormal channel activity and cell excitability. In silico analysis reveals that these variants functionally mimic the phosphorylated channel, resulting in increased susceptibility to arrhythmia-triggering afterdepolarizations. Finally, we report that this same motif is aberrantly regulated in a large-animal model of acquired heart disease and in failing human myocardium. CONCLUSIONS: We identify the mechanism for 2 human arrhythmia variants that affect Na(v)1.5 channel activity through direct effects on channel posttranslational modification. We propose that the CaMKII phosphorylation motif in the Na(v)1.5 DI-DII cytoplasmic loop is a critical nodal point for proarrhythmic changes to Na(v)1.5 in congenital and acquired cardiac disease.
BACKGROUND:Human gene variants affecting ion channel biophysical activity and/or membrane localization are linked to potentially fatal cardiac arrhythmias. However, the mechanism for many humanarrhythmia variants remains undefined despite more than a decade of investigation. Posttranslational modulation of membrane proteins is essential for normal cardiac function. Importantly, aberrant myocyte signaling has been linked to defects in cardiac ion channel posttranslational modifications and disease. We recently identified a novel pathway for posttranslational regulation of the primary cardiac voltage-gated Na(+) channel (Na(v)1.5) by Ca(2+)/calmodulin-dependent protein kinase II (CaMKII). However, a role for this pathway in cardiac disease has not been evaluated. METHODS AND RESULTS: We evaluated the role of CaMKII-dependent phosphorylation in human genetic and acquired disease. We report an unexpected link between a short motif in the Na(v)1.5 DI-DII loop, recently shown to be critical for CaMKII-dependent phosphorylation, and Na(v)1.5 function in monogenic arrhythmia and common heart disease. Experiments in heterologous cells and primary ventricular cardiomyocytes demonstrate that the humanarrhythmia susceptibility variants (A572D and Q573E) alter CaMKII-dependent regulation of Na(v)1.5, resulting in abnormal channel activity and cell excitability. In silico analysis reveals that these variants functionally mimic the phosphorylated channel, resulting in increased susceptibility to arrhythmia-triggering afterdepolarizations. Finally, we report that this same motif is aberrantly regulated in a large-animal model of acquired heart disease and in failing human myocardium. CONCLUSIONS: We identify the mechanism for 2 humanarrhythmia variants that affect Na(v)1.5 channel activity through direct effects on channel posttranslational modification. We propose that the CaMKII phosphorylation motif in the Na(v)1.5 DI-DII cytoplasmic loop is a critical nodal point for proarrhythmic changes to Na(v)1.5 in congenital and acquired cardiac disease.
Authors: Barry London; Michael Michalec; Haider Mehdi; Xiaodong Zhu; Laurie Kerchner; Shamarendra Sanyal; Prakash C Viswanathan; Arnold E Pfahnl; Lijuan L Shang; Mohan Madhusudanan; Catherine J Baty; Stephen Lagana; Ryan Aleong; Rebecca Gutmann; Michael J Ackerman; Dennis M McNamara; Raul Weiss; Samuel C Dudley Journal: Circulation Date: 2007-10-29 Impact factor: 29.690
Authors: Nicole M Ashpole; Anthony W Herren; Kenneth S Ginsburg; Joseph D Brogan; Derrick E Johnson; Theodore R Cummins; Donald M Bers; Andy Hudmon Journal: J Biol Chem Date: 2012-04-18 Impact factor: 5.157
Authors: Anne-Laure Leoni; Bruno Gavillet; Jean-Sébastien Rougier; Céline Marionneau; Vincent Probst; Solena Le Scouarnec; Jean-Jacques Schott; Sophie Demolombe; Patrick Bruneval; Christopher L H Huang; William H Colledge; Andrew A Grace; Hervé Le Marec; Arthur A Wilde; Peter J Mohler; Denis Escande; Hugues Abriel; Flavien Charpentier Journal: PLoS One Date: 2010-02-19 Impact factor: 3.240
Authors: Vladimir E Bondarenko; Gyula P Szigeti; Glenna C L Bett; Song-Jung Kim; Randall L Rasmusson Journal: Am J Physiol Heart Circ Physiol Date: 2004-05-13 Impact factor: 4.733
Authors: Lei Chen; Michelle L Marquardt; David J Tester; Kevin J Sampson; Michael J Ackerman; Robert S Kass Journal: Proc Natl Acad Sci U S A Date: 2007-12-19 Impact factor: 11.205
Authors: Sakima A Smith; Langston D Hughes; Crystal F Kline; Amber N Kempton; Lisa E Dorn; Jerry Curran; Michael Makara; Tyler R Webb; Patrick Wright; Niels Voigt; Philip F Binkley; Paul M L Janssen; Ahmet Kilic; Cynthia A Carnes; Dobromir Dobrev; Matthew N Rasband; Thomas J Hund; Peter J Mohler Journal: Am J Physiol Heart Circ Physiol Date: 2016-04-22 Impact factor: 4.733
Authors: Anthony W Herren; Darren M Weber; Robert R Rigor; Kenneth B Margulies; Brett S Phinney; Donald M Bers Journal: J Proteome Res Date: 2015-04-13 Impact factor: 4.466
Authors: Nataliya Dybkova; Stefan Wagner; Johannes Backs; Thomas J Hund; Peter J Mohler; Thomas Sowa; Viacheslav O Nikolaev; Lars S Maier Journal: Cardiovasc Res Date: 2014-05-08 Impact factor: 10.787